Parhofer Klaus G
Medizinische Klinik II, Klinikum der Universität Munchen, Grosshadern.
MMW Fortschr Med. 2007 Jun 21;149(25-26):41-3. doi: 10.1007/BF03365101.
GLP-1 receptor agonists such as exenatide are a group of new therapeutic agents that mimic the gut-derived incretin hormone GLP-1. These drugs stimulate insulin secretion while suppressing glucagon secretion, inhibit gastric motility, reduce appetite and hence, food intake. This group of drugs also induce reduction in fasting and postprandial glucose concentrations, HbA1c and ultimately lead to weight loss. The drugs are administered subcutaneously (exenatide twice daily). The most common side effect is mild nausea. Although short-term studies are promising, long-term clinical studies are needed to determine the benefits of this approach for the treatment of type 2 diabetes.
胰高血糖素样肽-1（GLP-1）受体激动剂，如艾塞那肽，是一类新型治疗药物，可模拟肠道来源的肠促胰岛素激素GLP-1。这些药物可刺激胰岛素分泌，同时抑制胰高血糖素分泌，抑制胃动力，降低食欲，从而减少食物摄入量。这类药物还可降低空腹和餐后血糖浓度、糖化血红蛋白（HbA1c），最终导致体重减轻。这些药物通过皮下注射给药（艾塞那肽每日两次）。最常见的副作用是轻度恶心。尽管短期研究前景乐观，但仍需要长期临床研究来确定这种治疗方法对2型糖尿病治疗的益处。
